HanchorBio Inc.
SAN FRANCISCO, CA and TAIPEI, TAIWAN / ACCESSWIRE / December 1, 2023 / HanchorBio Inc., a global clinical-stage biotechnology company focusing on the discovery and development of innovative immuno-biomedicines to treat a wide variety of patients suffering from hard-to-treat solid tumors or hematological malignancies, today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.Details of the presentation are as follows. The full abstracts will be made available on the ESMO website on Thursday, 30 November 2023 at 00:05 CET.
Title: An Engineered Ligand-Trap Biologic Targeting the CD47 Signaling Pathway for Cancer Treatment with Superb Efficacy and Safety Profiles
Presenter: Sean Juo, Ph.D., President and Chief Scientific Officer of HanchorBio
Location: Palexpo, Geneva, Switzerland
Presentation Number: #10951
Date and Time: Thursday, 7 December 2023 at 12:00-13:00 CET
Highlights from the Preclinical Data-
Key findings from the preclinical studies of HCB101 targeting the SIRPa- CD47 pathway include:
- HCB101 triggered strong phagocytic reactions against tumor cells but not red blood cells;
- HCB101 consistently showed excellent efficacy against hematological and solid malignancies in 14 human tumor xenograft models;
- Quantitative RNA transcriptional analysis indicated that HCB101 triggered drastic changes in gene expression inside the tumor compared to other competing molecules, suggesting a unique MOA underlying HCB101's superior efficacy;
- No adverse reaction was observed in cynomolgus monkey toxicology studies, indicating a good safety profile;
- HCB101 is currently being evaluated in a multi-regional, multi-center clinical study (NCT05892718) in the United States and Taiwan.
About HCB101
Discovered through structure-guided protein design which was further supplemented with relevant screening technologies, HCB101 is an engineered extracellular IgV domain of SIRPα fused to the Fc region of IgG4. HCB101 triggers potent phagocytic activity of macrophages by blocking the "do not eat" signal between macrophages and the tumor cells. Based on the extensive in-vitro and in-vivo preclinical data, HCB101 is potentially a much safer and more potent biologic than the anti-CD47 monoclonal antibodies and other SIRPα fusion proteins currently being investigated in clinical trials. Furthermore, quantitative RNA transcriptional analysis indicated that HCB101 triggered distinct gene expression profiles inside the tumor and in the tumor microenvironment compared to other relevant clinical candidates, suggesting that HCB101 might exhibit unique mechanisms of action. With IND clearance from the U.S. FDA and Taiwan FDA, HCB101 is currently being investigated in a multi-regional, multi-center, open-label, dose-finding clinical trial (NCT05892718) of adults with advanced solid tumors or relapsed and refractory non-Hodgkin lymphoma in the United States and Taiwan. Using HCB101 as the foundation, our multi-functional Fc-based designer biologics (FBDB™) platform pipeline includes other immune-modulating molecules targeting both adaptive and innate immunity to provide novel and efficacious treatments to patients suffering from difficult-to-treat cancers and other debilitating diseases.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio is a global clinical-stage biotechnology company focusing on immuno-oncology. The Company is led by an experienced team of pharmaceutical industry veterans with a proven track record of success in biologics discovery and global development to transcend current cancer therapies. Committed to reactivating the immune system to fight against diseases, the proprietary Fc-based designer biologics (FBDB™) platform enables unique biologics with diverse multi-targeting modalities to unleash both innate and adaptive immunity to overcome the current inadequacies of anti-PD1/L1 therapies. The FBDB™ platform has successfully delivered proof-of-concept data in several in vivo tumor animal models. By making breakthroughs in multi-functional innovative molecular configurations in R&D and improving the manufacturing process in CMC, HanchorBio develops transformative medicines to address unmet medical needs.
For more information, please visit HanchorBio or follow us on LinkedIn
Contact Information
Scott Liu
Founder, Chairman and CEO
scott_liu@hanchorbio.com
Yuehua Cong
Chief Business Officer
yuehua_cong@hanchorbio.com
SOURCE: HanchorBio Inc.
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/811807/hanchorbio-to-present-at-the-esmo-immuno-oncology-2023-annual-congress
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Latest GA Autonomous Jet Demo Features Live Air-to-Air Engagement Capability17.7.2025 18:10:00 CEST | Press release
Autonomous Tasking With TacACE and Optix.C2 Showcase Maturity and Operational Readiness SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and General Atomics Integrated Intelligence, Inc. (GA-Intelligence) successfully completed a groundbreaking demonstration on July 8, integrating technologies across multiple affiliates to showcase long-range kill chain effects, including an autonomous air-to-air engagement. The flight integrated local and global sensor fusion to deliver real-time situational awareness and autonomous tasking to an airborne MQ-20 Avenger® through the Tactical Autonomy Core Ecosystem (TacACE) to close the kill chain and showcase the system's maturity and operational readiness for the warfighter. The event featured the integration of a Collaborative Combat Aircraft (CCA), a fully compliant government-owned autonomy implementation, and beyond-line-of-sight (BLOS) Command and Control (C2). The MQ-20 unmanned jet,
Belgian Aircrew Completes MQ-9B Training17.7.2025 18:05:00 CEST | Press release
GA-ASI's MQ-9B SkyGuardian® Training Was Conducted at Multiple Sites, Including Flight Test & Training Center and Desert Horizon SAN DIEGO, CALIFORNIA / ACCESS Newswire / July 17, 2025 / The first Belgian aircrew has completed training to operate the world's leading remotely piloted aircraft (RPA): the MQ-9B SkyGuardian®. General Atomics Aeronautical Systems, Inc. (GA-ASI), designer and developer of the MQ-9B, provided the extensive aircrew training that culminated at GA-ASI's Desert Horizon test facility in El Mirage, California, following stops in Belgium and GA-ASI's Flight Test & Training Center in North Dakota. "Providing all-encompassing training for the aircrews of our customers goes hand in hand with delivering the world's most capable RPA," said GA-ASI President David R. Alexander. "Completing this training ensures that Belgium is ready and able to operate their MQ-9Bs and maximize the benefits that come from long-range, high-endurance RPA." The scope of the training is focuse
A New Transatlantic Partnership for European CCA17.7.2025 18:00:00 CEST | Press release
General Atomics announces plans for rapid international uncrewed fighter development FAIRFORD, UK / ACCESS Newswire / July 17, 2025 / General Atomics is taking a bold step toward rapidly delivering a European Collaborative Combat Aircraft (CCA) - based on a mature U.S. platform, assembled in Europe, with European mission systems - by aligning its independent U.S. and German aerospace affiliates under a teamed operation.YFQ-42A The new aircraft is derived from the U.S. Air Force's YFQ-42A prototype, currently in ground testing and scheduled for first flight later this summer, designed and built by General Atomics Aeronautical Systems, Inc. (GA-ASI) in San Diego, Calif. European mission system customization and manufacturing in Europe will be supported by General Atomics' German aerospace affiliate, General Atomics Aerotec Systems GmbH (GA-ATS), headquartered in Oberpfaffenhofen, near Munich. Leveraging the prior investments of these established aerospace companies on both sides of the A
The Digital Banker17.7.2025 15:30:00 CEST | Press release
In this July 2025 article for the Fast Company Executive Board, Avtar Sehmbi of the Forbes Technology Council explains why Chief Technology Officers (CTOs) are increasingly positioned to lead the future of banking. LONDON, GB / ACCESS Newswire / July 17, 2025 / Artificial intelligence (AI) and other emerging technologies are reshaping banking by automating tasks, enhancing data analysis, and enabling personalized services. These tools improve risk management, streamline operations, and boost profitability. Institutions like JPMorgan Chase and Bank of America are already leveraging AI for fraud detection, customer service, and advanced analytics. Meanwhile, AI-powered hedge funds and neobanks use technology to deliver tailored experiences and outperform their peers.Avtar Sehmbi The Digital Banker Fast Company Avtar Sehmbi the Digital banker This shift isn't theoretical; it's already well underway. Digital systems are fully embedded into the everyday operations of financial institutions,
Global Sports Brand U.S. Polo Assn. Launches First Retail Store in Berlin, Germany16.7.2025 16:37:00 CEST | Press release
Brand Targets Aggressive Retail, Wholesale and Ecommerce Expansion WEST PALM BEACH, FL AND BERLIN, GERMANY / ACCESS Newswire / July 16, 2025 / U.S. Polo Assn., the official brand of the United States Polo Association (USPA), is proud to announce its first retail store in Germany alongside its brand partners Incom S.p.a. and Modevertrieb Sarnacchiaro GmbH (MVS). The location of the first U.S. Polo Assn. store in the heart of Berlin is at the premier Alexa Mall at Alexanderplatz and marks the beginning of a strategic retail rollout across the country, which solidifies the multi-billion-dollar brand's global presence in Germany. The new Berlin store is offering a curated selection of men's, women's, undergarments, and beachwear collections - a perfect mix of sports heritage and contemporary spirit.U.S. Polo Assn. Executives J. Michael Prince, Antonio Sarnacchiaro, and Lorenzo Nencini with U.S. Polo Assn. Models U.S. Polo Assn. is a symbol of style that blends sports inspiration and authen
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom